DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Doxorubicin hydrochloride
Drug: Estramustine Phosphate Sodium
Drug: Flutamide
Drug: Nilutamide
Drug: Ketoconazole
Procedure: Conventional Surgery
Drug: Therapeutic Hydrocortisone
Drug: Vinblastine

First Posted Date: 2003-01-27

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 306

Registration Number: NCT00002855

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00006471

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy

Not Applicable

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Fatigue

Interventions: Biological: Epoetin alfa
Other: Placebo

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00052221

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00023881

Locations: 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States

Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00008411

Locations: 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Phase 3

Completed

Conditions: Melanoma
Skin Cancer

Interventions: Biological: Recombinant Interferon Alfa (IFN-A)
Biological: Aldesleukin (IL-2)
Drug: Cisplatin
Drug: Dacarbazine
Drug: Vinblastine
Procedure: Adjuvant Therapy

First Posted Date: 2003-01-27

Last Posted Date: 2011-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 140

Registration Number: NCT00002882

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer

Phase 3

Completed

Conditions: Drug-induced Nausea and Vomiting
Breast Cancer

Interventions: Procedure: management of therapy complications
Procedure: acupressure therapy
Procedure: nausea and vomiting therapy

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 57

Registration Number: NCT00046865

Locations: 🇺🇸
University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States
🇺🇸
H. Lee Moffitt Cancer Center CCOP Research Base, Tampa, Florida, United States

Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Phase 3

Completed

Conditions: Bladder Cancer

Interventions: Other: Placebo
Drug: Fenretinide

First Posted Date: 2003-01-27

Last Posted Date: 2018-11-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00004154

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Skin Neoplasms
Melanoma

Interventions: Drug: Imatinib mesylate (STI571)

First Posted Date: 2003-01-27

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00027586

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Temozolomide
Drug: R115777

First Posted Date: 2003-01-03

Last Posted Date: 2020-09-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00050986

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy